| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028254054 |
| P356 | DOI | 10.1007/S12035-012-8340-3 |
| P932 | PMC publication ID | 3589649 |
| P698 | PubMed publication ID | 22941028 |
| P5875 | ResearchGate publication ID | 230783273 |
| P2093 | author name string | Nadia Stefanova | |
| Lisa Fellner | |||
| P2860 | cites work | Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis | Q22241651 |
| The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia | Q22252705 | ||
| The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress | Q24301895 | ||
| p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies | Q24320549 | ||
| HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin | Q24337155 | ||
| Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease | Q24596763 | ||
| α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells | Q24633663 | ||
| Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein | Q24655848 | ||
| p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy | Q24682056 | ||
| Multiple system atrophy: a clinical and neuropathological perspective | Q26829838 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo | Q27860578 | ||
| Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. | Q40362975 | ||
| Grading of neuropathology in multiple system atrophy: proposal for a novel scale | Q40398217 | ||
| Alpha-synuclein overexpression in oligodendrocytic cells results in impaired adhesion to fibronectin and cell death | Q40418370 | ||
| Mutant alpha-synuclein overexpression mediates early proinflammatory activity | Q40778644 | ||
| Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. | Q40870297 | ||
| Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy | Q41078288 | ||
| Neuropathology of Parkinson's disease | Q41095404 | ||
| Accumulation of phosphorylated alpha-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy | Q42455519 | ||
| The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations | Q42469816 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease | Q42484469 | ||
| Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. | Q42486578 | ||
| Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease | Q42521775 | ||
| Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease | Q42571006 | ||
| Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). | Q43219125 | ||
| Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy? | Q43600606 | ||
| Glial cell death induced by overexpression of alpha-synuclein | Q43728426 | ||
| Tumor necrosis factor inhibits neurite outgrowth and branching of hippocampal neurons by a rho-dependent mechanism. | Q43875599 | ||
| Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. | Q43906992 | ||
| Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. | Q44086465 | ||
| Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function | Q44552114 | ||
| Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. | Q44702932 | ||
| Microglial activation parallels system degeneration in multiple system atrophy | Q44745872 | ||
| Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease | Q44769508 | ||
| Microglial MyD88 signaling regulates acute neuronal toxicity of LPS-stimulated microglia in vitro | Q44964904 | ||
| Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration | Q45062530 | ||
| Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. | Q45201632 | ||
| Microglial activation and dopamine terminal loss in early Parkinson's disease | Q45237159 | ||
| Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. | Q45297626 | ||
| alpha-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress | Q46097999 | ||
| Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease | Q46404588 | ||
| Role of activated astrocytes in neuronal damage: potential links to HIV-1-associated dementia | Q46493395 | ||
| Microglial cells and Parkinson's disease | Q46567817 | ||
| Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease | Q46593989 | ||
| A possible role for humoral immunity in the pathogenesis of Parkinson's disease | Q46748023 | ||
| Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro | Q46829340 | ||
| Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra | Q47397177 | ||
| Poor and protracted myelination as a contributory factor to neurodegenerative disorders | Q48116261 | ||
| Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease | Q48132477 | ||
| The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology | Q48142791 | ||
| Differential expression of interferon-gamma receptor on human glial cells in vivo and in vitro | Q48163261 | ||
| Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains | Q48187073 | ||
| Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein | Q48251119 | ||
| Argyrophilic glial inclusions in the midbrain of patients with Parkinson's disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein | Q48280288 | ||
| Non-steroidal anti-inflammatory drugs in Parkinson's disease | Q28222289 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction | Q28506296 | ||
| Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration | Q28587785 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains | Q29616293 | ||
| A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results | Q30407150 | ||
| Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice. | Q30494594 | ||
| Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease | Q30496234 | ||
| Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants | Q30991616 | ||
| Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons | Q33312931 | ||
| Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. | Q33526342 | ||
| Consensus statement on the diagnosis of multiple system atrophy. | Q33605440 | ||
| Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies | Q33726660 | ||
| CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes. | Q33757872 | ||
| Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study | Q33782156 | ||
| Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors | Q33958289 | ||
| Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure | Q34032393 | ||
| Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. | Q34287439 | ||
| The role of glial cells in Parkinson's disease | Q34318207 | ||
| Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes | Q34472472 | ||
| Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment | Q34524887 | ||
| HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. | Q34615988 | ||
| Clinical outcomes of progressive supranuclear palsy and multiple system atrophy | Q34767058 | ||
| Astrocytes in Parkinson's disease and DJ-1 | Q34792091 | ||
| α-Synuclein impairs macroautophagy: implications for Parkinson's disease. | Q35005567 | ||
| Expression of mutant alpha-synuclein modulates microglial phenotype in vitro | Q35014520 | ||
| Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). | Q35045422 | ||
| IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease | Q35064839 | ||
| Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons | Q35167964 | ||
| Description of Parkinson's disease as a clinical syndrome. | Q35170978 | ||
| Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease | Q35320917 | ||
| Neuropathological spectrum of synucleinopathies | Q35540178 | ||
| Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus | Q35692589 | ||
| Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. | Q35764504 | ||
| Glutathione peroxidase, glial cells and Parkinson's disease | Q48359939 | ||
| Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice | Q48388037 | ||
| Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies | Q48401512 | ||
| Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression | Q48405912 | ||
| Contribution of somal Lewy bodies to neuronal death | Q48557845 | ||
| Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline | Q48599725 | ||
| Some Immunohistochemical Features of Argyrophilic Grain Dementia With Normal Cortical Choline Acetyltransferase Levels but Extensive Subcortical Pathology and Markedly Reduced Dopamine | Q48601161 | ||
| Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. | Q48697425 | ||
| Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. | Q48786266 | ||
| Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. | Q48787937 | ||
| Inhibition of lipopolysaccharide-induced nitric oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. | Q48821941 | ||
| Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress. | Q48938738 | ||
| Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. | Q51804442 | ||
| alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. | Q52165042 | ||
| Activated microglia in dementia with Lewy bodies. | Q53236387 | ||
| [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. | Q53642827 | ||
| Genetic mouse models for Parkinson's disease display severe pathology in glial cell mitochondria. | Q54621912 | ||
| Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. | Q54626622 | ||
| Multiple system atrophy | Q56442789 | ||
| Dementia with Lewy bodies | Q57813917 | ||
| NSAID use and risk of Parkinson disease: a population-based case-control study | Q57950713 | ||
| Microglial activation mediates neurodegeneration related to oligodendroglial α-synucleinopathy: Implications for multiple system atrophy | Q59273827 | ||
| Survival in multiple system atrophy | Q63352447 | ||
| The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease | Q64797268 | ||
| NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains | Q64797306 | ||
| Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins | Q68015727 | ||
| Neuroinflammatory processes in Parkinson's disease | Q70606957 | ||
| Expression of the endocytosis regulatory proteins Rab5 and Rabaptin-5 in glial cytoplasmic inclusions from brains with multiple system atrophy | Q73629508 | ||
| Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats | Q73755556 | ||
| Microglia | Q81034804 | ||
| Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration | Q81589639 | ||
| Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions | Q83339692 | ||
| ??? | Q64767196 | ||
| Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury | Q35768729 | ||
| Pro-regenerative properties of cytokine-activated astrocytes. | Q35775364 | ||
| Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease | Q35918549 | ||
| Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. | Q36085162 | ||
| SNCA variants are associated with increased risk for multiple system atrophy | Q36460907 | ||
| Cellular pathology in multiple system atrophy | Q36589164 | ||
| "Minimal change" multiple system atrophy. | Q36751604 | ||
| Multiple system atrophy: a review of 203 pathologically proven cases | Q36852143 | ||
| Protein aggregation mechanisms in synucleinopathies: commonalities and differences | Q36994070 | ||
| The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease | Q37054679 | ||
| Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease | Q37211800 | ||
| Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration | Q37241917 | ||
| Multiple system atrophy: a primary oligodendrogliopathy. | Q37282526 | ||
| Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model | Q37289669 | ||
| Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival | Q37347595 | ||
| Neuroanatomy and pathology of sporadic Parkinson's disease. | Q37397139 | ||
| Gliogenesis: historical perspectives, 1839-1985. | Q37397181 | ||
| NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies | Q37591516 | ||
| Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update | Q37716685 | ||
| Microglia and neuroprotection: from in vitro studies to therapeutic applications | Q37770636 | ||
| Glia: initiators and progressors of pathology in Parkinson's disease | Q37842235 | ||
| Autophagic pathways in Parkinson disease and related disorders | Q37854912 | ||
| Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts | Q37874476 | ||
| Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy | Q38585651 | ||
| Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy | Q39340274 | ||
| Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. | Q39604586 | ||
| Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide | Q39821041 | ||
| Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. | Q39885727 | ||
| Astrocyte-secreted GDNF and glutathione antioxidant system protect neurons against 6OHDA cytotoxicity | Q39899392 | ||
| Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. | Q39980342 | ||
| Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease | Q39986517 | ||
| Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells | Q39997221 | ||
| Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease | Q40098160 | ||
| Synuclein activates microglia in a model of Parkinson's disease | Q40126232 | ||
| Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia | Q40197055 | ||
| Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells | Q40225441 | ||
| Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk | Q40269212 | ||
| Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. | Q40273125 | ||
| P433 | issue | 2 | |
| P921 | main subject | neuroglia | Q177105 |
| neurodegeneration | Q1755122 | ||
| cell | Q7868 | ||
| nerve tissue protein | Q6996861 | ||
| nervous system | Q9404 | ||
| Parkinson disease associated proteins | Q77946709 | ||
| P304 | page(s) | 575-586 | |
| P577 | publication date | 2012-09-02 | |
| 2013-04-01 | |||
| P1433 | published in | Molecular Neurobiology | Q15716645 |
| P1476 | title | The role of glia in α-synucleinopathies | |
| P478 | volume | 47 |
| Q36086721 | A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy |
| Q35544737 | Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy |
| Q60947930 | Extracellular Interactions of Alpha-Synuclein in Multiple System Atrophy |
| Q35627057 | Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy |
| Q26851153 | Glia and alpha-synuclein in neurodegeneration: A complex interaction |
| Q34491177 | Glucocerebrosidase mutations in primary parkinsonism |
| Q55085565 | Glutathione S-Transferase Alpha 4 Prevents Dopamine Neurodegeneration in a Rat Alpha-Synuclein Model of Parkinson's Disease. |
| Q38126332 | Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration |
| Q55242370 | Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived α-synuclein in oligodendroglia: implications for MSA pathogenesis. |
| Q59335641 | Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection? |
| Q36513407 | Models of multiple system atrophy |
| Q49562668 | Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy. |
| Q26771536 | Neuroinflammation in Multiple System Atrophy: Response to and Cause of α-Synuclein Aggregation |
| Q38173380 | Neuroprotective function of 14-3-3 proteins in neurodegeneration |
| Q35857994 | Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity |
| Q39152836 | Potential Modes of Intercellular α-Synuclein Transmission |
| Q47663712 | Potential clinical utility of multiple system atrophy biomarkers |
| Q35043731 | Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation |
| Q55691017 | Region-Specific Effects of Immunotherapy With Antibodies Targeting α-synuclein in a Transgenic Model of Synucleinopathy. |
| Q34548551 | Regulation of the mammalian heat shock factor 1. |
| Q26770919 | Review: Multiple system atrophy: emerging targets for interventional therapies |
| Q44294417 | Screening of Toll-like receptors expression in multiple system atrophy brains |
| Q38039857 | Targeting the chameleon: a focused look at α-synuclein and its roles in neurodegeneration |
| Q35833984 | The Interplay between Alpha-Synuclein Clearance and Spreading |
| Q38944057 | The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. |
| Q52374337 | The Role of LRRK2 in Neurodegeneration of Parkinson Disease. |
| Q35427654 | The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. |
| Q26853537 | The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease |
| Q33868678 | Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy |
| Q33797532 | Towards translational therapies for multiple system atrophy |
| Q48465555 | Transcriptome analysis of grey and white matter cortical tissue in multiple system atrophy |
Search more.